Cancers & treatments·Regimen libraryCurative

ABVE-PC

Checked 2026-09-09

Children and adolescents with intermediate- and high-risk Hodgkin lymphoma in Children's Oncology Group trials, response-adapted with or without radiotherapy

Also called ABVE-PC, ABVE.

One cycle

every 21 days × 4-5 · about 12 weeks in total

21-day cycle × 4-5 (about 12 weeks)IntravenousOral Daily oral course

Components

Drug	Dose	Route	Days
Doxorubicin Cytotoxic chemotherapy (anthracycline)	25 mg/m²	IV	D1, 2
Bleomycin Glycopeptide antibiotic (DNA-cleaving)	5 units/m² day 1, 10 units/m² day 8	IV	D1, 8
Vincristine Vinca alkaloid (microtubule inhibitor)	1.4 mg/m² (maximum 2.8 mg)	IV	D1, 8
Etoposide Topoisomerase II inhibitor (podophyllotoxin derivative)	125 mg/m²	IV	D1-3
Prednisone Glucocorticoid	40 mg/m² per day	Oral	D1-7
Cyclophosphamide Alkylating agent (oxazaphosphorine prodrug)	800 mg/m²	IV	D1

Cycles

4-5

21-day cycle

Emetogenicity

High (>90%)

G-CSF

Recommended

Notes

AHOD0031 showed that rapid early responders with a complete response can omit radiotherapy without loss of event-free survival.
Brentuximab vedotin replaces bleomycin in the successor regimen Bv-AVE-PC (AHOD1331).

Used in

Hodgkin lymphoma

Products

DoxorubicinBleomycinVincristineEtoposidePrednisoneCyclophosphamide

Source

Friedman (COG AHOD0031), JCO 2014: dose-intensive response-based chemotherapy and radiotherapy for children and adolescents

Reference doses for a typical adult from the cited protocol or label. Doses are adjusted for renal and hepatic function, age, performance status and prior toxicity, and institutional protocols vary. Verify against the current label and your local protocol before treating. Not medical advice.